Telix Pharmaceuticals Limited
TLXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Telix Pharmaceuticals Limited (TLX) is listed under Biotechnology. Valued at $3.19B, TLX is a mid-cap name in its sector. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Market Cap
$3.19B
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
39.61
EPS (TTM)
$-0.02
EPS (Fwd)
$0.24
ROE
-1.9%
ROA
1.1%
Cash
$141.9M
Total Debt
$467.1M
Free CF
-$36.7M
52W Change
-43.9%
Annual Financials
Cash vs Debt
On the balance sheet, TLX has $141.9M in cash with $467.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$36.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -1.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $108.9M (2022) to $803.8M (2025), reflecting a 638% increase over the period.
TLX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TLX.